We are a biopharmaceutical company established in 1995 focused on developing products for the treatment of cancer and infectious diseases based on our proprietary Tarmogen® platform. Tarmogens activate a subset of white blood cells called T cells that destroy infected or malignant cells, in contrast to traditional vaccines, which predominately stimulate antibody production. We have two Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications.
Strategic collaboration and option agreement with Celgene for cancer. In May 2009, we entered into a worldwide strategic collaboration and option agreement with Celgene focused on the discovery, development and commercialization of certain product candidates for the treatment of cancer. For product candidates subject to option by Celgene, we are responsible for initial development under the agreement, and Celgene has the option to license each of them at specific points in the development plan. Upon the achievement of certain development, regulatory and commercial milestones, we would be eligible to receive milestone payments and tiered royalties based on net sales of each licensed product. Under this agreement, in July 2013 Celgene exercised its option for a worldwide, exclusive license to the GI-6300 program, including GI-6301, which is a Tarmogen program targeting the brachyury protein. In July 2015, Celgene exercised its option for a worldwide, exclusive license to the GI-6200 program, including GI-6207, which targets carcinoembryonic antigen, or CEA.
National Institutes of Health (NIH) – Cooperative Research and Development Agreement. We are party to a Cooperative Research and Development Agreement (CRADA) originally signed in May 2008 and renewed in October 2013, with the NIH. The CRADA is for the preclinical and clinical development of our proprietary yeast-based Tarmogens expressing tumor-associated antigens as potential vaccines for the prevention and/or therapy of a range of human cancers.